arrow
C

Chihiro Morishima

university of washington
H指数:47
被引数:9,075

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase II pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor (INCB024360) plus a multipeptide melanoma vaccine (MELITAC 12.1) in patients with advanced melanoma, with sequential evaluation of the tumor microenvironment

晚期黑色素瘤患者中吲哚胺2,3-双加氧酶-1(IDO1)抑制剂(INCB024360)联合多肽黑色素瘤疫苗(MELITAC 12.1)的II期初步试验,并序贯评估肿瘤微环境

2026-10-020
OAAI
T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity
2022-05-2325
OAAI
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses
2022-03-1639
OA
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
2021-08-2745
OAAI
Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity
2021-08-1840
OAAI
Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates
2021-02-0156
OA
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets

Flt3配体通过扩大树突状细胞亚群增强对anti-DEC-205-NY-ESO-1疫苗的免疫反应

2020-11-1679
PREAI
Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019

冠状病毒病患者新型冠状病毒核衣壳和刺突蛋白抗体检测的敏感性2019

2020-05-19214
OAAI
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors

新型重组IL15复合物ALT-803在晚期实体瘤患者中的I期试验

2018-11-15162
OAAI